Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701958 | 0.83 | IDO1 (0.47) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL27192280 | 0.83 | MAPT (0.43) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL31341468 | 0.83 | MAPT (0.43) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL7002979 | 0.78 | SLC9A1 (0.67) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL6902353 | 0.78 | SLC9A1 (0.67) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL5775091 | 0.78 | SLC9A1 (0.67) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL23425327 | 0.76 | MAPT (0.58) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2563497 | 0.76 | MAPT (0.58) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL3737728 | 0.76 | MAPT (0.58) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL23116564 | 0.76 | MAPT (0.58) | SLC9A1ALDH1A1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | SLC9A1 3960/4885ALDH1A1 3259/4885MAPT 2197/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | SLC9A1 3960/4885ALDH1A1 3259/4885MAPT 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.